Abdomen

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Retrieved on: 
Wednesday, March 27, 2024
Community, Patient, Colostomy, Health care, Bacteria, Quality of life, Shoe, Curriculum, Western world, Abdominal pain, IBD, Immune system, Diarrhea, Disease, Health professional, Crohn's disease, Student, Environment, Caregiver, Incidence, Empathy, Abdomen, Inflammatory bowel disease, HY

DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE. The initiative, focused on raising awareness of the difficult symptoms of Inflammatory Bowel Disease (IBD), entailed an immersive 24-hour simulation that generated a deeper understanding of how the disease affects the daily lives of patients.

Key Points: 
  • DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE.
  • While inflammation is the body's natural reaction to irritation or injury, in patients with IBD, it is thought that the body's own immune system mistakenly identifies a harmless food or bacteria within the gut as 'foreign' and attacks it3.
  • Using a mobile app and an 'IBD kit,' participants engaged in common struggles, gaining insights into the disease's physical and emotional challenges.
  • Although the simulation couldn't fully replicate the experience, it is meant to foster empathy for individuals living with IBD.

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Retrieved on: 
Tuesday, March 26, 2024
Avicenna, Pulmonary embolism, Brain, Algorithm, Radiology, La Ciotat, NCCT, Pelvis, Radiodensity, Stroke, Abdomen, Mortality, Triage, AI, Aortic dissection, CINA, Deep learning, Google Images, Intracranial hemorrhage, Machine learning, Probability, FDA, Physician, Health, Embolism, Food, Medical imaging

La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

Key Points: 
  • La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products.
  • Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
  • CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging.
  • "The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care.

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Retrieved on: 
Tuesday, March 26, 2024
Avicenna, Pulmonary embolism, Brain, Algorithm, Radiology, La Ciotat, NCCT, Pelvis, Radiodensity, Stroke, Abdomen, Mortality, Triage, AI, Aortic dissection, CINA, Deep learning, Google Images, Intracranial hemorrhage, Machine learning, Probability, FDA, Physician, Health, Embolism, Food, Medical imaging

La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

Key Points: 
  • La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products.
  • Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
  • CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging.
  • "The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care.

Imaging with [99m]Tc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery

Retrieved on: 
Friday, March 15, 2024
Diagnosis, Uncertainty, Histology, Growth, Infertility, Cyst, Disease, University, Pelvis, Endometrioma, Patient, Rectum, Abdomen, Laparoscopy, Endometriosis, Society, Integrin, Woman, SRI, Pain, University of Oxford, FDA, Medical imaging

The imaging findings were compared to the surgical and histology reports and indicate that 99mTc-maraciclatide holds potential as a non-invasive test for early-stage endometriosis.

Key Points: 
  • The imaging findings were compared to the surgical and histology reports and indicate that 99mTc-maraciclatide holds potential as a non-invasive test for early-stage endometriosis.
  • Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford added: "Endometriosis is a common disease affecting many millions of women worldwide with pain and infertility.
  • Therefore, a novel imaging tool to assist healthcare professionals in identifying or ruling out the disease is urgently needed."
  • At the Endometriosis CaRe Centre at the University of Oxford our studies focus on identifying novel genetic, diagnostic and therapeutic targets for endometriosis.

10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring

Retrieved on: 
Monday, March 11, 2024
CSFS, PSFS, Biotechnology, Elective surgery, Bruise, Patient, SAN, Abdomen, American Academy, MD, Clinician, Clinical trial, American Academy of Dermatology, Erythema, ITT, FAAD, Pain, AAD, FDA, Organic acid, Edema, Annual general meeting, Pharmaceutical industry

SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101. An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.

Key Points: 
  • SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio , LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101.
  • An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.
  • "10XB101 has the appropriate product-market fit to capture the tremendous opportunity for submental contouring.
  • In addition, its attributes hold promise for potential expansion to other body contouring applications, such as treatment of the abdomen and flanks."

Law Firm of Cerri, Boskovich & Allard Files a Lawsuit Over the Alleged Sexual Abuse of a San Jose Jr. Sharks Hockey Player

Retrieved on: 
Thursday, March 7, 2024
Sports, Professional Services, Legal, Hockey, General Sports, Multimedia, San Francisco Bay Area, NHL, Entertainment, Abdomen, Ice, USA Hockey, Sharks Sports and Entertainment, Parent, Sharks Ice San Jose, Human, Sport, Athlete, Massage, Shark

The law firm of Cerri, Boskovich & Allard has filed a lawsuit alleging that a San Jose Jr.

Key Points: 
  • The law firm of Cerri, Boskovich & Allard has filed a lawsuit alleging that a San Jose Jr.
  • Sharks hockey player was sexually abused due to the negligence of Sharks Sports & Entertainment, LLC and its subsidiary, Sharks Ice, LLC.
  • Sharks Sports and Entertainment is a privately held company that owns the San Jose Sharks and several sports-related properties throughout the Bay Area.
  • Whitmer, the lawsuit claims, would take the young victim alone into the locker room at Sharks Ice, the ice-skating facility and the official training facility of the NHL's San Jose Sharks.

Nu Skin Launches RenuSpa iO, a New Personalized Beauty and Wellness Device

Retrieved on: 
Tuesday, February 27, 2024
Nu Skin Enterprises, Skin, FDA, Overalls, Abdomen, Buttocks, NUS, Massage, Thigh, Beauty

PROVO, Utah, Feb. 27, 2024 /PRNewswire/ -- Nu Skin Enterprises (NYSE: NUS), a global beauty and wellness leader, today introduced Nu Skin RenuSpa iO, a smart beauty and wellness device designed to promote overall wellness and body confidence through skin stimulation. RenuSpa iO is an FDA-cleared microcurrent body device and the latest innovation from the world's best-selling brand for beauty device systems for six consecutive years.*

Key Points: 
  • The new self-care system uses unique adaptive microcurrent technology to help the body restore, revitalize and refresh through skin stimulation
    PROVO, Utah, Feb. 27, 2024 /PRNewswire/ -- Nu Skin Enterprises (NYSE: NUS), a global beauty and wellness leader, today introduced Nu Skin RenuSpa iO, a smart beauty and wellness device designed to promote overall wellness and body confidence through skin stimulation.
  • RenuSpa iO is an FDA-cleared microcurrent body device and the latest innovation from the world's best-selling brand for beauty device systems for six consecutive years.
  • "We've expanded our best-selling beauty device portfolio to now include our first integrated beauty and wellness device," said Ryan Napierski, president and CEO at Nu Skin.
  • "RenuSpa iO is game-changing technology for the global beauty and wellness market," said Steve Hatchett, executive vice president and chief product officer at Nu Skin.

United Imaging Showcases AI-Driven Innovations and Expands European Presence at ECR 2024

Retrieved on: 
Friday, February 23, 2024
One Solution, UAI, ACS, Growth, Abdomen, Radiology, Perception, Bionics, Pelvis, SAT, University, ECR, Diagnosis, UMR, Neurology, Robotics, MRI, Software, CARE, CE, 3D, Radio, Extrapyramidal system, Brain, UII, SCAN, Safety, UDP, Yale University, Research, Workflow, Philosophy, MSK, 2D, Umi, AI, Cardiology, Thought, Signal-to-noise ratio, Joint, UC, University of California, Davis, Patient, DSA, Medical device

VIENNA, Feb. 23, 2024 /PRNewswire/ -- United Imaging, a global leader in medical technology, is showcasing its full portfolio of AI-empowered innovations at the European Society of Radiology (ECR) 2024 in Vienna, Austria.

Key Points: 
  • VIENNA, Feb. 23, 2024 /PRNewswire/ -- United Imaging, a global leader in medical technology, is showcasing its full portfolio of AI-empowered innovations at the European Society of Radiology (ECR) 2024 in Vienna, Austria.
  • At United Imaging, all our innovations are AI-driven, enhancing clinical workflows and supporting diverse scenarios, solidifying our commitment to delivering value to the global medical community.
  • In five years, United Imaging has introduced hundreds of systems and reached 16 European countries, offering efficient and professional service.
  • Highlighting the growth at ECR 2024, United Imaging will feature the uMR Jupiter 5T (not CE marked in EU) at ECR 2024, a revolutionary whole-body 5T MRI system.

FEELINGIRL Announces Brand Upgrade and New Products for Every Age, Every Stage

Retrieved on: 
Tuesday, February 20, 2024
System, Breathability, Woman, Abdomen, Element, Marriage, Emotion, Workplace, All Day, Human, Buttocks, Retail

With the tagline "Undergarments for Every Age, Every Stage," FEELINGIRL is committed to becoming a lifelong partner for consumers, offering body shaping solutions that cater to every age and stage of life.

Key Points: 
  • With the tagline "Undergarments for Every Age, Every Stage," FEELINGIRL is committed to becoming a lifelong partner for consumers, offering body shaping solutions that cater to every age and stage of life.
  • FEELINGIRL champions a minimalist yet elegant style, using high-quality fabrics to meticulously craft its garments.
  • To achieve a perfect blend of elegance and comfort, FEELINGIRL incorporates unique techniques as the brand's key design elements.
  • FEELINGIRL recognizes that each stage of life brings unique emotions and experiences.

Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver

Retrieved on: 
Tuesday, February 13, 2024
DSM-IV codes, Non-alcoholic fatty liver disease, Coronary artery disease, NAFLD, CT scan, Spine, Artificial intelligence, AI, MD, Osteoporosis, American Journal, Obesity, FDA, Cardiovascular disease, Food, Abdomen, Risk, Cirrhosis, Hepatology, Liver disease, Prevalence, University, MASH, Type 2 diabetes, AJR, Death, The Company, Patient, Diagnosis, Software, CAC, Medicine, Medical imaging

PETACH TIKVA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for HealthFLD, an artificial intelligence (AI) software that provides automated qualitative and quantitative analysis of liver attenuation from routine contrast and non-contrast chest and abdomen CT scans in patients between the ages of 18 to 75. HealthFLD is intended to support clinicians in the detection of fatty liver, correlated with hepatic steatosis, an early sign of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD).

Key Points: 
  • HealthFLD is intended to support clinicians in the detection of fatty liver, correlated with hepatic steatosis, an early sign of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD).
  • MASLD is commonly asymptomatic until it progresses to advanced liver fibrosis, and the current gold standard for diagnosis is a liver biopsy, which is invasive and costly.
  • HealthFLD was designed to help clinicians in the assessment and analysis of fatty liver in the general population from routine CT scans.
  • It’s promising to have a liver solution available that may help evaluate early signs of illness from routine imaging.”
    The HealthFLD clearance is the third product across the Nanox AI suite of population health solutions to receive FDA clearance.